## CONSORT 2010 checklist

Title:

No:

Date:

Type of article:

Review article
Original article
Short communication
Case report
National Report
Letter to Editor
RCT

Referee name:

Section/topic	Item	Checklist item	Yes	No	Comments
	No.				
		241 -			
Title					
Is the title	1	Identification as a randomized			
	Ab	trial in the title?			
	Abstract				
Is structured	2	Structured summary of trial design, methods, results, and			
summary		conclusions?			
	Intro	duction			
Is rationale	3				
is rationale	3	Scientific background and explanation of rationale?			
Is objectives	4	Specific objectives or			
15 00 jeeu ves mi		hypotheses?			
	Me	thods			
IsTrial design	5	Description of trial design (such	-		
1911 lai ucsign	5	as parallel, factorial) including			
		allocation ratio?			
		Important changes to methods			
		after trial commencement (such			
		as eligibility criteria), with			
		reasons?			
Is Participants	6	Eligibility criteria for			
15 1 <b>u</b> 000 <b>p</b> 000 <b>m</b>	Ũ	participants?			
		Settings and locations where the			
		data were collected?			
<b>TTA A</b>	7				
Is Interventions	7	The interventions for each group with sufficient details to allow			
		replication, including how and			
		when they were actually			
		administered?			
Is Outcomes	8	Completely defined pre-			
		specified primary and secondary			
		outcome measures, including			
		how and when they were			
		assessed?			
		Any changes to trial outcomes			
		after the trial commenced, with			
		reasons?			

Is Sample size	9	How sample size was			
15 Sample size	9	determined?			
	10		┝──┝		
	10	When applicable, explanation of			
		any interim analyses and			
	11	stopping guidelines?	<u> </u>		
Is Randomisation?	11	1-Method used to generate the			
		random allocation sequence?			
		2-Type of randomisation; details			
		of any restriction (such as			
		blocking and block size)?			
		blocking and block size)?			
		3-Mechanism used to implement			
		the random allocation sequence			
		(such as sequentially numbered			
		containers), describing any steps			
		taken to conceal the sequence			
		until interventions were assigned			
		?			
		4-Who generated the random			
		allocation sequence, who			
		enrolled participants, and who			
		assigned participants to			
		interventions?			
		5 If dono who was blinded often			
		5-If done, who was blinded after			
		assignment to interventions (for			
		example, participants, care			
		providers, those assessing outcomes) and how?			
		outcomes) and now?			
		6-If relevant, description of the			
		similarity of interventions?			
		similarly of mor ventions:			
		7- Statistical methods used to			
		compare groups for primary and			
		secondary outcomes?			
		8- Methods for additional			
		analyses, such as subgroup			
		analyses and adjusted analyses?			
	 PF(	SULTS			
	NEA				
Is Results?		1- For each group, the numbers			
		of participants who were			
		randomly assigned, received			

[]				
	intended treatment, and were			
	analysed for the primary			
	outcome?			
	2- For each group, losses and			
	exclusions after randomisation,			
	together with reasons?			
	3- Dates defining the periods of			
	recruitment and follow-up?			
	*			
	4- Why the trial ended or was			
	stopped?			
	stopped.			
	5- A table showing baseline			
	demographic and clinical			
	characteristics for each group?			
	6 For each many states f			
	6- For each group, number of			
	participants (denominator)			
	included in each analysis and			
	whether the analysis was by			
	original assigned groups?			
	7 For each primary and			
	7- For each primary and			
	secondary outcome, results for			
	each group, and the estimated			
	effect size and its precision (such			
	as 95% confidence interval)?			
	8- For binary outcomes,			
	presentation of both absolute and			
	relative effect sizes is			
	recommended?			
	0. Describe of an arthur and			
	9- Results of any other analyses			
	performed, including subgroup			
	analyses and adjusted analyses,			
	distinguishing pre-specified			
	from exploratory?			
	10- All important harms or			
	unintended effects in each			
	group?			
DISC	DISCUSSION			

Is Limitations	24	Trial limitations, addressing			
15 Emilations	24	sources of potential bias,			
		-			
		imprecision, and, if relevant,			
		multiplicity of analyses?			
Is Generalisability	25	Generalisability (external			
		validity, applicability) of the trial			
		findings?			
		Interpretation consistent with			
		results, balancing benefits and			
		harms, and considering other			
		relevant evidence?			
Is conclusions	26	Provide a general interpretation			
		of the results in the context of			
		other evidence, and implications			
		for future research?			
	FUNDING		I		
Is funding	27	Describe sources of funding for			
		the systematic review and other			
		support (e.g., supply of data);			
		role of funders for the systematic			
		review?			

## **Additional comments**

Which of the following do you suggest about the publication of this article in the university scientific journal?

☐Accept in present form ☐Accept with minor changes ☐Accept with major changes ☐Reject Thank you for your cooperation Office of the English Language Journal of Chronic Diseases <u>http://cdjournal.muk.ac.ir/index.php/cdj/issue/archive</u> Magazine Office Email: <u>pakanzadf@gmail.com</u> Phone: 6664658-0871 / 8245 Fax: 6664654-0871